clinical dataOsivax misses Phase 2b flu vaccine endpoint, shifts focus to combinationsFrench-Belgian biotech Osivax has reported disappointing Phase 2b results for its broad-spectrum influenza vaccine OVX836, which achieved a nonsignificant efficacy estimate of 24% against a predefined … more ➔
AppointmentsEvotec fills CSO vacancy; Sibylla and AL-S Pharma name new CEOsEvery Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell us about the companies they join. This week: a swift scientific leadership change … more ➔
fundraisingMicrobiotica raises £36M to test gut-bacteria capsule in ulcerative colitisU.K. microbiome company Microbiotica has raised £36 million (€43 million), the first close of a Series C round led by the British Business Bank, to take its ulcerative colitis drug MB310 into Phase … more ➔
CAR-T cell therapyLakefront offloads CAR-T programs to Armed Cell as Mankind Pharma takes control of the Belgian startupLakefront Biotherapeutics, formerly Galapagos, has sold five preclinical CAR-T assets to Belgian startup Armed Cell Therapeutics for €8 million upfront, while India’s Mankind Pharma has agreed to acquire … more ➔
fundraisingOMass raises $310M in Europe’s second-largest biotech round of 2026Oxford-based OMass Therapeutics has raised $310 million (€276 million) in a Series C financing to advance its small-molecule pipeline in endocrinology and immunology, including a potential treatment … more ➔
clinical dataBioNTech’s mRNA cancer vaccine misses Phase 2/3 endpointBioNTech’s BNT113, combined with Keytruda, failed to significantly improve progression-free survival in a Phase 2/3 head and neck cancer trial. The study will continue to assess whether the combination … more ➔
obesityZealand taps Generate’s AI discovery engine in $1.2B obesity dealZealand Pharma will pay Generate Biomedicines $30 million (€27 million) upfront to discover protein drugs for obesity and other metabolic diseases, broadening its pipeline beyond peptides and small … more ➔
Meanwhile in biotechLundbeck starts Phase 2; Rewind secures funding; Beactica picks a degraderBeyond the main headlines, European biotech kept moving this week. Lundbeck and Neurosterix advanced neurological drug programs, Rewind secured funding for myelin repair, and Beactica selected a cancer … more ➔
startupUndecimal raises $18M to take siRNA beyond the liverUndecimal Bio has launched with $18 million (about €16 million) in seed funding to develop delivery molecules that carry gene-silencing medicines beyond the liver, initially targeting kidney and vascular … more ➔
obesityRoche’s China shopping spree continues with $1B Rona obesity pactRoche has licensed worldwide rights to Rona Therapeutics’ experimental ALK7-targeting RNA interference therapy for obesity and metabolic diseases, offering up to $100 million (about €89 million) … more ➔
